DMI-Logo
search-iconsearch-icon
Home
>
Strategic Insights

Strategic Insights - Competitive Intelligence

Access exclusive insights, competitive benchmarks, and pharma intelligence reports designed to power data-driven decisions. Stay ahead of the curve with expert-curated strategies, market foresight, and deep competitive analysis.

Know more about our Pharmaceutical Competitive Intelligence Services

Therapy Areas

Allergy & RespiratoryCardiologyDermatologyEndocrinologyEndocrinology & MetabolismGastrointestinalGenitourinaryHematologyInfectious DiseaseMusculoskeletalNeurologyOncologyOphthalmologyRare DiseasesUrologyBiosimilarsVaccinesCell & Gene Therapy
search-icon
Blogs

October 2026

Neurofibromatosis Type 1 (NF1) Market Intelligence: Strategic Insights into a High-Unmet-Need Segment | Competitive Intelligence

Explore the NF1 competitive landscape, KOSELUGO, GOMEKLI, Fumaining, emerging therapies, clinical pipelines, market forecasts and unmet medical needs.

Blogs

October 2026

Primary Biliary Cholangitis (PBC) Market: Competitive Landscape, Approved Therapies, Pipeline Analysis, and Forecast, 2026–2035

Explore the PBC competitive landscape, IQIRVO and LIVDELZI sales, LYNAVOY, emerging pipeline therapies, FDA milestones, market forecasts and unmet needs.

Blogs

October 2026

U.S. and EU Biosimilars Competitive Intelligence Report: Approved Products, Pipeline Analysis, Competitive Landscape and Market Forecast to 2035

Gain edge in US & EU biosimilars market with strategic pharmaceutical CI report. Track approved biosimilars, pricing, market access, insights and growth forecasts.

Blogs

October 2026

Myelofibrosis (MF) Competitive Intelligence Report: Approved Therapies, Pipeline Landscape, Market Positioning and Strategic Outlook

Analyze the myelofibrosis market, FDA-approved treatments, emerging drug pipeline, JAK inhibitor combinations, competitive landscape and market forecast through 2035.

Blogs

October 2026

Revolutionizing Polycythemia Vera (PV) Management: The Rise of First-in-Class and Best-in-Class Agents | Competitive Intelligence

Explore the polycythemia vera market, approved therapies, clinical pipeline, rusfertide competition, emerging treatment mechanisms and global market forecast through 2035.

Blogs

October 2026

Diabetic Retinopathy Competitive Intelligence Report: Approved Therapies, Pipeline Landscape, Market Positioning and Strategic Outlook

Analyze the diabetic retinopathy market, FDA-approved therapies, emerging pipeline assets, key competitors, treatment innovation and global market outlook through 2035.

  • Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 13
  • Next

Know more about our Pharmaceutical Competitive Intelligence Services or

Check out our Blogs on Competitive Intelligence